# Acalabrutinib Maleate and Bortezomib for Patients With HLA Antibodies

> **NCT07635511** · PHASE3 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 42 (estimated)

## Conditions studied

- Hematological Malignancies
- Platelet Transfusion Refractoriness (PTR)
- HLA Antibodies

## Interventions

- **DRUG:** Acalabrutinib maleate
- **DRUG:** bortezomib
- **OTHER:** HLA-matched or crossmatched irradiated platelets
- **DRUG:** human immune globulin

## Key facts

- **NCT ID:** NCT07635511
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2029-01-01
- **Final completion:** 2029-05-31
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07635511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07635511, "Acalabrutinib Maleate and Bortezomib for Patients With HLA Antibodies". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07635511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*